Receive our newsletter – data, insights and analysis delivered to you
  1. News
April 15, 2020

KD Pharma and SLA Pharma to study EPAspire for Covid-19

KD Pharma Group and SLA Pharma are set to conduct a clinical trial of drug candidate EPAspire to potentially treat Covid-19 symptoms.

KD Pharma Group and SLA Pharma are set to conduct a clinical trial of drug candidate EPAspire to potentially treat Covid-19 symptoms.

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) approved the trial, which will investigate the ability of the drug candidate to decrease the mortality risk in severely ill patients.

The companies are currently in discussions with authorities in other European countries. An application has been filed with the US Food and Drug Administration (FDA).

Enrolment for the trial is set to begin soon and more hospital sites are being added.

KD Pharma CEO Oscar Groet said: “We hope EPAspire will be able to reduce the risk of coronavirus complications progressing to serious outcomes like ARDS, the need for artificial ventilation, and intensive care.

“This unique preparation has potential, to not only modify the Covid-19 disease process, reducing harmful, excess inflammatory responses, but to do so without suppressing the immune response to the virus, which are vital to seroconversion, giving the patient ongoing protection against continued viral challenge.”

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

EPAspire is made of purified eicosapentaenoic acid free fatty acid (EPA-FFA) in gastro-resistant capsules. It is delivered to the gut at optimal pH to ensure maximal absorption.

Trial participants will receive the drug candidate within one day of hospitalisation and the treatment will be continued for one month with a follow-up of two weeks.

Patients will be assessed for disease progression to more serious outcomes and inflammation markers.

EPAspire is currently in a clinical trial in Europe to treat familial adenomatous polyposis (FAP).

The company said that the FAP trial data indicates that the drug candidate suppresses expression of inflammatory cytokines, which are thought to be associated with the progression of Covid-19 symptoms.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU